CAS 935888-69-0: Oprozomib
Formula:C25H32N4O7S
InChI:InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1
InChI key:InChIKey=SWZXEVABPLUDIO-WSZYKNRRSA-N
SMILES:C([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@@H](NC(=O)C2=CN=C(C)S2)COC)=O)COC)=O)(=O)[C@@]3(C)CO3
Synonyms:- ONX 0912
- Oprozomib
- O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide
- PR 047
- L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-
Sort by
Found 8 products.
Oprozomib
CAS:Proteosome inhibitor; pro-apoptotic; has anti-myeloma activityFormula:C25H32N4O7SPurity:Min. 95%Color and Shape:White To Off-White SolidMolecular weight:532.61 g/molOprozomib
CAS:Oprozomib inhibits 20S proteasome β5/LMP7, is orally available, and may have cancer-fighting properties. IC50: β5 - 36 nM; LMP7 - 82 nM.Formula:C25H32N4O7SPurity:98% - 99.87%Color and Shape:SolidMolecular weight:532.61Oprozomib
CAS:Controlled ProductApplications Oprozomib is the second class of proteasome inhibitors with higher specificities and reduced toxicities, against head and neck squamous cell carcinoma. References Zang, Y., et al.: Autophagy., 8, 1837 (2012); Zang, Y., et al.: Clin. Cancer. Res., 18, 5639 (2012); Mato, A.R., et al.: Oncologist., 17, 694 (2012); Zhou, H.J., et al.: J. Med. Chem., 52, 3028 (2009);Formula:C25H32N4O7SColor and Shape:NeatMolecular weight:532.61
![Oprozomib [ONX 0912]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F7W%2Fthumb%2FGW2060.jpg&w=3840&q=75)
